The combination therapy demonstrated acceptable safety and a 60% objective response rate (ORR) in BRCA-mutated ovarian cancer patients, including partial and complete responses. Higher baseline PD-L1 expression and CD8+ T-cell infiltration were associated with responders, highlighting potential biomarkers for treatment selection. This evidence concerns the gene CD8A and ovarian cancer.